MP-13 GreenLight laser prostatectomy: Are outcomes sustainable after a decade of surgery? A single-center experience with up to 15 years’ follow-up
Saturday June 29, 2019 from 21:45 to 22:15
TBD
Presenter

Ahmed Ibrahim, Canada

Urology fellow

Division of Urology, Depatment of surgery

McGill University Health Center

Abstract

GreenLight laser prostatectomy: Are outcomes sustainable after a decade of surgery? A single-center experience with up to 15 years’ follow-up

Ahmed Ibrahim1, Nawar Touma1, Ahmad M. AlShammari1, Serge Carrier1, Mélanie Aube-Peterkin1.

1Division of Urology, Department of Surgery, McGill University Health Center , McGill University, Montreal, QC, Canada

Introduction: Since its introduction in 2005, GreenLight laser has been widely adopted as a convenient source of energy for surgical treatment of benign prostatic hyperplasia (BPH). However, there is paucity in the literature quantifying long-term outcomes (> 10 years) of GreenLight laser prostatectomy. Herein, we report our single-center experience with long-term outcomes over a period of 15 years.

Methods: Between 2005 and 2020, a prospectively maintained database for patients undergoing GreenLight photovaporization of the prostate (PVP) for symptomatic BPH was reviewed. Three Generations of Green Light Laser were used over this time period.  Patients with ≥10-years follow-up were included. Demographic and perioperative data were collected together with the International Prostate Symptoms Score (IPSS), Quality of Life (QoL), peak flow rate (Qmax), post-void residual urine (PVR), and PSA changes. In addition, perioperative and late adverse events were recorded.

Results: After a mean follow-up of 12.1 years (10-15 years), 124 patients were included with a mean age of 73.9 (range: 54- 85) years and a mean preoperative prostate size of 72.4±15.3mL. Demographic and perioperative data are presented in Table 1. The blood transfusion rate was 2.4%. Development of bladder neck contracture and urethral stricture were encountered in 9 (7.3%) and 7 (5.6%) of patients. Six (4.8%) patients required repeat surgery for adenoma regrowth. Additionally, there were significant reductions in mean IPSS, QoL, and PVR (% reductions were 60.4% and 65%, and 72.6%, respectively; P< 0.001) at the most recent follow-up (Table 2). Likewise, there was a significant increase in Qmax (8.2 to 17.7 ml/sec, p<0.001) with PSA reduction by 64.2 % compared to its baseline value (Table 2).

Conclusions: Our long-term functional outcomes support the durability of the GreenLight laser prostatectomy with acceptable long-term adverse events after a decade of surgery.

 

 


© 2022 CUA 74th Annual Meeting